MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Begins Patient Enrollment and Dosing in Phase II NV-387 Ebola Trial

NanoViricides, Inc. (NYSE American: NNVC) announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo Ebolavirus and other Ebola viruses has begun enrolling and dosing patients at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (“DRC”). The Phase IIA portion began enrollment and […]